Fed. Circ. Backs PTAB’s Invalidation Of J&J Remicade Patent

Law360, New York (January 23, 2018, 9:03 PM EST) -- The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a Johnson & Johnson patent on the blockbuster autoimmune disease drug Remicade for double patenting, in a win for Pfizer Inc., which launched a biosimilar version in 2016.

The appeals court rejected the argument by Johnson & Johnson’s Janssen Biotech Inc. unit that its patent was protected by a safe harbor provision from the PTAB’s ex parte reexamination decision that it was unpatentable for obviousness-type double patenting based on other Janssen patents....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd.


Case Number

17-1120

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

October 28, 2016


Case Title

In re: Janssen Biotech, Inc.


Case Number

17-1257

Court

Appellate - Federal Circuit

Nature of Suit

Date Filed

November 22, 2016

Law Firms

Companies

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.